Teachers Retirement System of The State of Kentucky trimmed its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 1.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 110,662 shares of the company’s stock after selling 1,200 shares during the period. Teachers Retirement System of The State of Kentucky owned about 0.09% of Ionis Pharmaceuticals worth $5,611,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Hanseatic Management Services Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after purchasing an additional 41 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Ionis Pharmaceuticals by 0.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock worth $492,000 after purchasing an additional 43 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its holdings in shares of Ionis Pharmaceuticals by 0.3% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock worth $1,241,000 after purchasing an additional 65 shares during the last quarter. World Asset Management Inc boosted its holdings in shares of Ionis Pharmaceuticals by 3.4% during the 2nd quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock worth $286,000 after purchasing an additional 187 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Ionis Pharmaceuticals by 9.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after purchasing an additional 311 shares during the last quarter. Institutional investors own 90.22% of the company’s stock.

Several brokerages have recently weighed in on IONS. Stifel Nicolaus boosted their target price on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a report on Wednesday, August 9th. BMO Capital Markets boosted their target price on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Sunday, September 17th. Evercore ISI began coverage on Ionis Pharmaceuticals in a report on Wednesday, August 16th. They set an “outperform” rating and a $65.00 target price on the stock. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $50.31.

Shares of Ionis Pharmaceuticals, Inc. (IONS) opened at $54.53 on Monday. The company has a market cap of $6,805.13, a P/E ratio of 363.53 and a beta of 2.90. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals, Inc. has a 12-month low of $37.26 and a 12-month high of $65.51.

In other news, SVP Patrick R. O’neil sold 1,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total transaction of $55,000.00. Following the sale, the senior vice president now owns 10,633 shares of the company’s stock, valued at approximately $584,815. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Stanley T. Crooke sold 27,500 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $52.89, for a total transaction of $1,454,475.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 110,886 shares of company stock worth $6,391,045. Corporate insiders own 2.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals, Inc. (IONS) Shares Sold by Teachers Retirement System of The State of Kentucky” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/ionis-pharmaceuticals-inc-ions-shares-sold-by-teachers-retirement-system-of-the-state-of-kentucky/1728408.html.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.